EGFR-IN-109_product_DataBase

Bioactivity	EGFR-IN-109 (compound 4) is an EGFR inhibitor, with the IC50 values of 25.8 and 182.3 nM for EGFRWT and EGFRT790M, respectively. EGFR-IN-109 arrests the cancer cells’ growth at the G2/M phase and induces both early and late apoptosis. EGFR-IN-109 can be used in cancer research[1].
Invitro	EGFR-IN-109 (compound 4) (0-20 μM, 2 days) 抑制高表达 EGFR 细胞 MCF-7 和 A549 的增殖，IC50 值分别为 13.06 和 20.13 μM[1]。EGFR-IN-109 (13.06 μM, 24 h) 通过将细胞生长阻滞在 G2/M 期促进 A549 细胞凋亡[1]。EGFR-IN-109 (13.06 μM, 72 h) 促进 A549 细胞中的 caspase-3、caspase-9 和 BAX 的蛋白表达，下调 Bcl-2 的蛋白表达[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> EGFR-IN-109 相关抗体: Cell Proliferation Assay[1] Cell Line:
CAS	3019971-97-9
Formula	C12H16N4OS
Molar Mass	264.35
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Sobh EA, et al. Computer aided drug discovery (CADD) of a thieno[2,3-d]pyrimidine derivative as a new EGFR inhibitor targeting the ribose pocket. J Biomol Struct Dyn. 2024 Mar;42(5):2369-2391.

PeptideDB